Metabolism Disorder TRIZ Cases

Combines ETC-1002 with statins to lower low-density lipoprotein cholesterol levels through dual pathway inhibition.

Composite wax and saccharide layers reinforce microcapsule shells, resolving the trade-off between wall strength and payload capacity.

High-concentration SNAC salt protects peptides from gastrointestinal degradation, resolving low oral bioavailability.

Humanin analogs treat myocardial injury by increasing insulin sensitivity via IGFBP-3 inhibition.

TrkB agonist antibodies resolve the trade-off between glycemic control and body weight by activating TrkB-mediated signaling pathways.

A transdermal pergolide formulation uses a specialized solvent system to achieve high drug solubility for consistent systemic absorption.

High-dose pitavastatin therapy lowers LDL-C below 70 mg/dL and reduces adverse cardiovascular events despite insufficient safety evidence for Asian populations.

Combining MIC-1 with leptin overcomes leptin resistance to induce significant weight loss while maintaining lean mass in obese subjects.

Modified exendin-4 peptides enhance GIP selectivity to lower glucose while avoiding GLP-1 antagonism and nausea.

Benzamide derivatives dissipate mitochondrial proton gradients to reduce lipid accumulation and inhibit cancer cell proliferation.

Albumin-free stabilizers prevent aggregation in insulin-Fc conjugates, eliminating viral risks while extending half-life.

A long-acting insulin conjugate linked to an immunoglobulin Fc region via a non-peptidyl linker.

Cold-gelated whey protein microcapsules shield probiotics from gastric acid and thermal damage.

TRABID protein stabilizes VPS34 via deubiquitination to boost autophagy, addressing ineffective obesity treatments.

Neuraminidase inhibitors restore glycocalyx volume and endothelial function, resolving contradictions where statin treatments increase hyaluronidase activity.

Segmented conjugation preserves protein potency while extending blood half-life and reducing production costs.

Anti-Npt2B antibody blocks intestinal phosphate absorption to manage hyperphosphatemia without vitamin D side effects.

Modified mutant collagenase targets white fat vasculature to break down adipose tissue through enzymatic hydrolysis.

An enteric coating uses cetyl alcohol and triethyl citrate plasticizers to deliver acid-labile drugs.

Anti-TIMP-2 antibodies neutralize TIMP-2 to improve kidney histology scores and estimated glomerular filtration rate in acute kidney injury.

A mu-opioid antagonist and GABA B agonist combination targets specific neural pathways to suppress sugar and fat consumption.

A composite pharmaceutical formulation combining Corylus heterophylla nut, Alnus japonica stem, and Sorbus commixta fruit extracts to alleviate physiological hangover symptoms.

A nutraceutical composition containing sulfated polysaccharides, Astragalus polysaccharides, and resveratrol reduces body fat and increases lean mass.

An enzyme cocktail cleaves gluten oligopeptides into non-toxic fragments.

Biglycan treats obesity by inhibiting Agrp and NPY expression while promoting POMC, avoiding cardiovascular side effects of synthetic drugs.

Combines calcium channel blockers with incretin agents to stimulate insulin secretion.

A vector system encoding BAX and sGAD65 induces tolerogenic immune responses to reverse hyperglycemia.

Oxidized hop product degrades bitter acids to suppress fat accumulation without taste masking.

A lectin-based carrier delivers therapeutic enzymes into cells via carbohydrate interactions.

Exosomes from mesenchymal stem cells regulate the ILK signaling pathway to restore tissue function.

Leonurine crystals from Chinese Motherwort offer a low-toxicity alternative to treat insulin resistance syndrome and hyperlipidemia.

ANGPTL8-binding antibodies reduce triglyceride levels and increase HDL-cholesterol without the side effects of conventional therapeutics.

Caricain enzyme breaks down toxic gluten peptides into non-toxic fragments, allowing patients to consume gluten without adverse effects.

Boronic acid cross-linkers create trehalose hydrogels that shield enzymes from thermal denaturation while enabling glucose-responsive release.

Cancer-associated fibroblasts encapsulate pancreatic beta cells to prevent immune rejection and ensure stable insulin production.

Lactam bridges in oral GLP receptor agonists resist proteolytic degradation, improving intestinal function.

Double-acylated GLP-1 derivatives attach albumin binding moieties to specific lysine residues.

Encapsulated probiotics in a pre-fermented cereal matrix protect viability against environmental factors, extending shelf-life and reducing contamination risks.

Decellularized extracellular matrix microparticles resolve the trade-off between immune protection and structural support, ensuring long-term cell viability.

Liver-targeted peptide inhibitors block alpha-amylase activity, reducing gastrointestinal side effects while controlling blood glucose levels.

Segmented oligomeric compounds enhance nuclease stability while reducing immunostimulatory activity to improve therapeutic efficacy.

A pharmaceutical composition combining oleoylethanolamide with beta-aminoisobutyric acid to regulate appetite and enhance fatty acid oxidation.

Butanol stabilizes vitamin B12 against light degradation without the toxicity of benzyl alcohol.

Hepatic-targeted glucokinase activators lower blood glucose through liver metabolism while avoiding pancreatic stimulation that causes hypoglycemia.

An extract from Hedychium coronarium leaves stimulates insulin release only when blood glucose is elevated.

A nutrient composition combining fenugreek and cinnamon extracts lowers fasting blood sugar and insulin levels through synergistic action.

Specific salt forms maintain Akt kinase inhibition under high temperature and humidity.